IN2012DN03368A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03368A
IN2012DN03368A IN3368DEN2012A IN2012DN03368A IN 2012DN03368 A IN2012DN03368 A IN 2012DN03368A IN 3368DEN2012 A IN3368DEN2012 A IN 3368DEN2012A IN 2012DN03368 A IN2012DN03368 A IN 2012DN03368A
Authority
IN
India
Prior art keywords
fragment
fusion
variant
derivative
inflammation
Prior art date
Application number
Inventor
Martina Kalle
Nils Martin Malmsten
Praveen Papareddy
Victoria Rydengard
Artur Schmidtchen
Bjorn Ulrik Walse
Original Assignee
Ximmune Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ximmune Ab filed Critical Ximmune Ab
Publication of IN2012DN03368A publication Critical patent/IN2012DN03368A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from a naturally occurring protein which modulates blood coagulation, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, for use in the treatment or prevention of inflammation and/or excessive coagulation of the blood. Related aspects of the invention provide isolated polypeptides comprising or consisting of an amino acid sequence of SEQ ID NOs: 1 to 11, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, which exhibit an anti¬inflammatory and/or anti-coagulant activity, together with isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of inflammation and/or excessive coagulation.
IN3368DEN2012 2009-09-22 2010-09-22 IN2012DN03368A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0916578.8A GB0916578D0 (en) 2009-09-22 2009-09-22 Polypeptides and uses thereof
PCT/GB2010/001781 WO2011036445A2 (en) 2009-09-22 2010-09-22 Polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
IN2012DN03368A true IN2012DN03368A (en) 2015-10-23

Family

ID=41278086

Family Applications (2)

Application Number Title Priority Date Filing Date
IN2981DEN2012 IN2012DN02981A (en) 2009-09-22 2010-09-21
IN3368DEN2012 IN2012DN03368A (en) 2009-09-22 2010-09-22

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IN2981DEN2012 IN2012DN02981A (en) 2009-09-22 2010-09-21

Country Status (12)

Country Link
US (2) US9169315B2 (en)
EP (2) EP2480244A1 (en)
JP (2) JP2013505030A (en)
CN (2) CN102655874B (en)
AU (2) AU2010299630A1 (en)
BR (2) BR112012006502A2 (en)
CA (2) CA2774288A1 (en)
EA (1) EA201200515A1 (en)
GB (1) GB0916578D0 (en)
IN (2) IN2012DN02981A (en)
MX (1) MX2012003425A (en)
WO (2) WO2011036444A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014003787A2 (en) * 2011-08-23 2020-10-27 Synapse B.V. thermostable blood coagulation system activation inhibitors by contact with foreign surfaces
RU2476231C1 (en) * 2011-10-11 2013-02-27 Федеральное государственное бюджетное учреждение "Российский научный центр "Восстановительная травматология и ортопедия" имени академика Г.А. Илизарова" Министерства здравоохранения и социального развития Российской Федерации Method for reducing necrosis of incisional wound edges following ankle replacement
GB2500184A (en) * 2012-03-12 2013-09-18 Ximmune Ab Polypeptide derived from helix A of heparin cofactor II
CN104292309B (en) * 2014-09-29 2017-04-12 广西中医药大学 Micro-molecule polypeptide
WO2016104436A1 (en) * 2014-12-22 2016-06-30 国立大学法人 岡山大学 Cytokine storm inhibitor
RU2606836C2 (en) * 2015-03-12 2017-01-10 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Anticoagulant, antiplatelet and fibrin-depolymerization complex based on heparin, method of its production and use
RU2610433C1 (en) * 2016-02-17 2017-02-10 Людмила Анисимовна Ляпина Anticoagulant
CN107875372A (en) * 2017-12-20 2018-04-06 辽宁师范大学 Recombinant peptide rLj 112 is preparing the application in cooperateing with anticoagulant heparin medicine
CN108338163A (en) * 2018-03-28 2018-07-31 陈太师 A kind of preparation method of holding effect type Biocidal algae-killing agent
WO2019230509A1 (en) * 2018-05-31 2019-12-05 国立大学法人 岡山大学 Reactive oxygen production inhibitor and/or scavenging promoter
EP3815706A4 (en) * 2018-06-28 2022-03-16 National University Corporation Okayama University AGENT FOR IMPROVING THE PHAGOCYTOTIC ABILITY OF NEUTROPHILS
EP3837549A1 (en) * 2018-08-16 2021-06-23 Roche Diagnostics GmbH Circulating tfpi-2 (tissue factor pathway inhibitor 2) in the assessment of atrial fibrillation and anticoagulation therapy
CN109432513B (en) * 2018-12-12 2021-03-23 中国医科大学 A kind of biological material with anti-thrombotic re-formation function and preparation method thereof
US11904000B2 (en) 2019-05-06 2024-02-20 Brown University Compositions and methods to enhance cutaneous wound healing
EP3946420A4 (en) * 2020-05-26 2022-06-08 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Methods and compositions for treatment of coronavirus infection and associated coagulopathy
CN114113601A (en) * 2020-08-25 2022-03-01 张曼 Application of urine heparin cofactor II and polypeptide fragment thereof in burn
CN117534731B (en) * 2021-09-24 2024-10-29 深圳市海伦海生物科技有限公司 Anticoagulant peptide and application thereof in anticoagulant products
CN114886116B (en) * 2022-03-18 2023-11-21 广东丸美生物技术股份有限公司 Composition for conditioning health of women of child bearing age, preparation method and beverage thereof and application
CN116510074A (en) * 2023-03-13 2023-08-01 西南交通大学 Preparation method of choline phosphate functionalized implantable titanium stent
CN116836233B (en) * 2023-08-31 2023-11-14 中国农业大学 Anti-inflammatory active polypeptide and application thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
SE459005B (en) 1985-07-12 1989-05-29 Aake Rikard Lindahl SET TO MANUFACTURE SPHERICAL POLYMER PARTICLES
US5102995A (en) * 1989-10-20 1992-04-07 Washington University Dna encoding modified heparin cofactor ii
US5118793A (en) * 1989-10-20 1992-06-02 Washington University Modified heparin cofactor II
US5643872A (en) 1989-10-23 1997-07-01 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
AU1873092A (en) 1991-04-09 1992-11-17 Brigham And Women's Hospital Chimeric molecule with plasminogen activator activity and affinity for atherosclerotic plaques
US6008058A (en) 1993-06-18 1999-12-28 University Of Louisville Cyclic peptide mixtures via side chain or backbone attachment and solid phase synthesis
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
US5712247A (en) * 1995-02-21 1998-01-27 University Of North Carolina Use of lactoferrin to modulate and/or neutralize heparin activity
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
JPH09176040A (en) * 1995-12-27 1997-07-08 Green Cross Corp:The Pharmaceutical use of heparin cofactor II
US6946439B2 (en) * 1997-02-06 2005-09-20 Entre Med, Inc. Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments
AU2878199A (en) * 1998-02-27 1999-09-15 University Of North Carolina At Chapel Hill, The Mutant heparin cofactor ii
WO2001036632A2 (en) * 1999-11-17 2001-05-25 Compugen Ltd. Variants of alternative splicing
EP1469887A4 (en) * 2001-07-20 2006-01-11 Eidgenoess Tech Hochschule COMPOSITIONS AND METHODS FOR USE AS BIOACTIVE AGENTS OF SULFATED AND SULFONATED AMINO ACIDS
GB0131112D0 (en) 2001-12-31 2002-02-13 Univ London Pharmacy Block copolymers
WO2003101398A2 (en) * 2002-05-31 2003-12-11 University Of Utah Research Foundation Variants of antithrombin iii
AU2003294401C1 (en) * 2002-11-22 2008-09-18 Ansun Biopharma, Inc. Broad spectrum anti-viral therapeutics and prophylaxis
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
WO2005015206A2 (en) * 2003-08-08 2005-02-17 Genova Ltd. Secreted polypeptide species associated with cardiovascular disorders
MXPA06010587A (en) * 2004-03-17 2007-03-29 Chiron Corp Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi).
US20050261241A1 (en) * 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
CN101400365A (en) * 2005-05-06 2009-04-01 诺华有限公司 Use of TFPI to treat severe bacterial infections
EP1913025A2 (en) * 2005-07-22 2008-04-23 Novartis AG Anti-microbial agents that interact with the complement system
ES2661002T3 (en) * 2005-12-29 2018-03-27 The Regents Of The University Of California Procedures and compositions related to the Kunitz I mutant domain of TFPI-2
WO2007079096A2 (en) * 2005-12-29 2007-07-12 Dyax Corp. Protease inhibition
WO2007091959A1 (en) * 2006-02-10 2007-08-16 Dermagen Ab Novel antimicrobial peptides and use thereof
SG174077A1 (en) * 2007-04-13 2011-09-29 Catalyst Biosciences Inc Modified factor vii polypetides and uses thereof
AU2008279129A1 (en) * 2007-07-24 2009-01-29 Nexbio, Inc. Technology for the preparation of microparticles

Also Published As

Publication number Publication date
AU2010299631A1 (en) 2012-05-03
WO2011036444A4 (en) 2011-06-23
BR112012006502A2 (en) 2016-08-16
JP2013505286A (en) 2013-02-14
JP2013505030A (en) 2013-02-14
WO2011036445A2 (en) 2011-03-31
EP2480564A2 (en) 2012-08-01
US20120177715A1 (en) 2012-07-12
GB0916578D0 (en) 2009-10-28
IN2012DN02981A (en) 2015-07-31
CN102655874A (en) 2012-09-05
CA2774296A1 (en) 2011-03-31
CN102639556A (en) 2012-08-15
AU2010299630A1 (en) 2012-04-26
BR112012006501A8 (en) 2017-07-11
CN102655874B (en) 2015-06-10
BR112012006501A2 (en) 2016-08-16
EP2480244A1 (en) 2012-08-01
CA2774288A1 (en) 2011-03-31
WO2011036444A1 (en) 2011-03-31
US9169315B2 (en) 2015-10-27
MX2012003425A (en) 2012-10-09
US20120189673A1 (en) 2012-07-26
AU2010299630A2 (en) 2012-05-03
EA201200515A1 (en) 2012-10-30
WO2011036445A3 (en) 2011-09-01

Similar Documents

Publication Publication Date Title
IN2012DN03368A (en)
WO2011036442A3 (en) Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders
NZ602943A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
PH12019500694A1 (en) Factor viii compositions and methods of making and using the same
EP3372617A3 (en) Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
MX2011008094A (en) Extended recombinant polypeptides and compositions comprising same.
MX2009012650A (en) Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders.
WO2010115998A3 (en) Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
EP2470670A4 (en) Coagulation factor vii compositions and methods of making and using same
EP4450523A3 (en) Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
MX2009002816A (en) Albumin fusion proteins.
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
PH12012502272A1 (en) Biological materials related to her3
EA201190326A8 (en) GROWTH HORMONE POLYPEPTIDES AND METHODS FOR THEIR PRODUCTION AND APPLICATION
WO2011123830A3 (en) Alpha 1-antitrypsin compositions and methods of making and using same
RU2016146198A (en) THERAPEUTIC DLL4-BINDING PROTEINS
MX2019002345A (en) Artificial nucleic acid molecules for improved protein or peptide expression.
HK1200842A1 (en) Proteins with improved half-life and other properties
MX359953B (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein.
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
BR112014024282A2 (en) bradykinin b1 receptor binding antibodies
WO2009001260A3 (en) Cosmetic use of apolipoprotein d type proteins
WO2010007144A3 (en) Mutated netrin-4 proteins, fragments thereof and their uses as drugs
WO2011135222A3 (en) Use of peptides as transporters intended for the internalization of molecules of interest into target cells
WO2010103515A3 (en) Compositions and methods for prevention and treatment of neurodegenerative diseases